Replies to post #158598 on Biotech Values

[DonShimoda]

JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths

http://bloodjournal.hematologylibrary.org/content/119/12/2721.full.pdf

[biopearl]

I see Don kindly provided the link. Worth reading the Geron statements post ASH in Dec as well as a perusal of the slides from the presentation available on the Geron web site. It appears they are emphasizing the potential to modify the underlying disease and have molecular confirmation of JAK 2 suppression which may set them apart from current therapies. bp